You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 15, 2024

LUXIQ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Luxiq, and what generic alternatives are available?

Luxiq is a drug marketed by Norvium Bioscience and is included in one NDA.

The generic ingredient in LUXIQ is betamethasone valerate. There are sixty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the betamethasone valerate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Luxiq

A generic version of LUXIQ was approved as betamethasone valerate by FOUGERA PHARMS INC on August 31st, 1983.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LUXIQ?
  • What are the global sales for LUXIQ?
  • What is Average Wholesale Price for LUXIQ?
Summary for LUXIQ
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 64
Patent Applications: 4,875
Drug Prices: Drug price information for LUXIQ
What excipients (inactive ingredients) are in LUXIQ?LUXIQ excipients list
DailyMed Link:LUXIQ at DailyMed
Drug patent expirations by year for LUXIQ
Drug Prices for LUXIQ

See drug prices for LUXIQ

Paragraph IV (Patent) Challenges for LUXIQ
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LUXIQ Foam betamethasone valerate 0.12% 020934 1 2007-08-10

US Patents and Regulatory Information for LUXIQ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Norvium Bioscience LUXIQ betamethasone valerate AEROSOL, FOAM;TOPICAL 020934-001 Feb 28, 1999 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LUXIQ

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Norvium Bioscience LUXIQ betamethasone valerate AEROSOL, FOAM;TOPICAL 020934-001 Feb 28, 1999 ⤷  Sign Up ⤷  Sign Up
Norvium Bioscience LUXIQ betamethasone valerate AEROSOL, FOAM;TOPICAL 020934-001 Feb 28, 1999 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LUXIQ

See the table below for patents covering LUXIQ around the world.

Country Patent Number Title Estimated Expiration
Denmark 0813413 ⤷  Sign Up
China 1179720 ⤷  Sign Up
Mexico 9706698 COMPOSICION FARMACEUTICA QUE CONTIENE CORTICOSTEROIDES. (CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION.) ⤷  Sign Up
United Kingdom 9504265 ⤷  Sign Up
Australia 709320 ⤷  Sign Up
Slovakia 119097 CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION ⤷  Sign Up
Japan H11501045 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.